18F-FES PET/CT in Imaging Patients With Desmoid Tumors
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | April 2015 |
| End Date: | December 2018 |
Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors
This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron
emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors.
18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off
radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may
show where tumor cells with estrogen receptors can be found in the body.
emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors.
18F-FES binds to estrogen receptors, which are present on desmoid tumors, and gives off
radiation that may be detected by PET and CT scans. The PET/CT scan forms an image that may
show where tumor cells with estrogen receptors can be found in the body.
PRIMARY OBJECTIVES:
I. Establish the avidity of desmoid tumors on 18F-FES PET/CT imaging. II. Correlate 18F-FES
PET avidity with degree of estrogen receptor (ER) expression by immunohistochemistry (IHC).
OUTLINE:
Patients undergo 18F-FES PET/CT imaging over 30 minutes.
After completion of study, patients are followed up for 30 days.
I. Establish the avidity of desmoid tumors on 18F-FES PET/CT imaging. II. Correlate 18F-FES
PET avidity with degree of estrogen receptor (ER) expression by immunohistochemistry (IHC).
OUTLINE:
Patients undergo 18F-FES PET/CT imaging over 30 minutes.
After completion of study, patients are followed up for 30 days.
Inclusion Criteria:
- Patients with biopsy-proven extra-abdominal desmoid tumors
- Not currently on estrogen medication for birth control, menopause, or other reason
- No anti-estrogen therapy for desmoid tumor within the past 6 months
- Both sporadic desmoid tumors and those associated with familial adenomatous polyposis
(FAP) syndromes will be included
Exclusion Criteria:
- Pregnancy or nursing patients
- Patients who do not wish to participate
We found this trial at
1
site
2220 Pierce Ave
Nashville, Tennessee 37232
Nashville, Tennessee 37232
615-936-8422
Principal Investigator: Katherine Hartley
Phone: 615-343-7185
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Click here to add this to my saved trials
